Scholars Central

Conference abstractPublished 27 Jun 2016

Intellectual Property Issues in Global Biosimilar Programs

Authors: Christoph Volpers

Michalski Hüttermann & Partner, Germany

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

In addition to development, manufacturing and commercial challenges, patent legal issues have a major impact on the success of a global biosimilar program. The multidimensional complexity of the patent landscape relating to a biosimilar candidate is due to the variety of categories of patent rights, encompassing, e.g., compound, process, formulation, indication, dosage and device patents; to the territorial diversity in scope and term of patent protection; to the technical complexity of biopharmaceutical production; and to the rapidly evolving, often controversial case law in this field. All these aspects need to be addressed when it comes to freedom-to-operate analysis and clearance of biosimilar projects, but is also relevant for securing one’s own IP position by filing and prosecuting applications on, e.g., improved process, formulation or device features. The talk will discuss challenges and chances along those lines and will give relevant examples. An update will be provided on some recent developments in patent law which will have an impact on future biologics and biosimilars patent landscapes in major markets, such as the Unitary Patent in Europe and the evolving biosimilars legislation in the US.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels